Catalyst Wire Dossier Catalyst Wire Dossier

Chimeric Switch Receptor Modified T Cells

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Chimeric Switch Receptor Modified T Cells, covering 2016-10-12 to 2016-10-12. Get the full timeline:

Most recent: Clinical Trial Update: Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors [Phase 1]

See pricing